At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
Cilofexordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function
In Brief
A Phase 1 clinical trial evaluating Cilofexor for Nonalcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC). Completed, enrolled 57 participants across 5 sites in 2 countries.
Detailed Summary
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNew Zealand, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedJun 21, 2016
Enrollment StartJul 13, 2016
Primary CompletionOct 16, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.0 years ago
Interventions
Cilofexordrug
Tablet(s) administered orally in a fed state on Day 1